Acquired platelet disorders
Open Access
- 11 November 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1638994
Abstract
Platelets are essential to primary hemostasis, and defects in their number or function can lead to clinically significant bleeding or thrombosis. Acquired platelet disorders are far more common than the inherited forms and arise in a wide range of settings, including drug exposure, autoimmune, systemic, and critical illnesses. This review examines current understanding of the mechanisms driving acquired platelet dysfunction and outlines the diagnostic and therapeutic approaches that are shaping contemporary standards of care. Drug-related and immune-mediated platelet defects remain the most recognized causes in clinical practice. Nevertheless, increasing evidence points to inflammation, particularly the profound dysregulation seen in sepsis, as a major contributor to abnormal platelet behavior. Although sepsis-associated platelet defects are frequent in practice and correlate with organ injury and adverse outcomes, they are rarely acknowledged in traditional frameworks of “acquired platelet disorders,” which tend to focus on classic hematologic and pharmacologic causes. This review summarizes current evidence on acquired platelet disorders and emphasizes the clinical and pathophysiologic relevance of sepsis-induced platelet dysfunction.Keywords
This publication has 162 references indexed in Scilit:
- The 2023 ACR/EULAR Antiphospholipid Syndrome Classification CriteriaArthritis & Rheumatology, 2023
- Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2023
- Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trialsAmerican Journal of Hematology, 2018
- Thrombopoietin mimetics for patients with myelodysplastic syndromesCochrane Database of Systematic Reviews, 2017
- Clinical utility of closure times using the platelet function analyzer‐100/200American Journal of Hematology, 2016
- Is ITP a thrombophilic disorder?American Journal of Hematology, 2015
- Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low/intermediate‐1–risk myelodysplastic syndrome and thrombocytopeniaCancer, 2014
- Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patientsAmerican Journal of Hematology, 2009
- A new case of acquired Glanzmann's thrombasthenia: Diagnostic value of flow cytometryCytometry Part B: Clinical Cytometry, 2008
- Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacityHepatology, 2006